SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Harris ED Jr.Rheumatoid arthritis: pathophysiology and implications for therapy.N Engl J Med1990;322:127789.
  • 2
    Miossec P.An update on the cytokine network in rheumatoid arthritis.Curr Opin Rheumatol2004;16:21822.
  • 3
    Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J, et al.A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.Arthritis Rheum2012;64:97081.
  • 4
    Fleischmann R.Novel small-molecular therapeutics for rheumatoid arthritis.Curr Opin Rheumatol2012;24:33541.
  • 5
    Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB.An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.N Engl J Med2010;363:130312.
  • 6
    Moller Dohn U, Boonen A, Hetland ML, Hansen MS, Knudsen LS, Hansen A, et al.Erosive progression is minimal, but erosion healing rare, in patients with rheumatoid arthritis treated with adalimumab: a 1 year investigator-initiated follow-up study using high-resolution computed tomography as the primary outcome measure.Ann Rheum Dis2009;68:158590.
  • 7
    Boumans MJ, Thurlings RM, Yeo L, Scheel-Toellner D, Vos K, Gerlag DM, et al.Rituximab abrogates joint destruction in rheumatoid arthritis by inhibiting osteoclastogenesis.Ann Rheum Dis2012;71:10813.
  • 8
    Hoy MD, O'Donnell JL, Hart DN.Dual CD45RA, CD45RO positive T-lymphocytes within rheumatoid arthritic joints.Pathology1993;25:16773.
  • 9
    Nanki T, Hayashida K, El-Gabalawy HS, Suson S, Shi K, Girschick HJ, et al.Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+ T cell accumulation in rheumatoid arthritis synovium.J Immunol2000;165:65908.
  • 10
    Burger JA, Zvaifler NJ, Tsukada N, Firestein GS, Kipps TJ.Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell-derived factor-1- and CD106 (VCAM-1)- dependent mechanism.J Clin Invest2001;107:30515.
  • 11
    Mittal GA, Joshi VR, Deshpande A.Stromal cell-derived factor-1α in rheumatoid arthritis.Rheumatology (Oxford)2003;42:9156.
  • 12
    Kanbe K, Takagishi K, Chen Q.Stimulation of matrix metalloprotease 3 release from human chondrocytes by the interaction of stromal cell–derived factor 1 and CXC chemokine receptor 4.Arthritis Rheum2002;46:1307.
  • 13
    Grassi F, Cristino S, Toneguzzi S, Piacentini A, Facchini A, Lisignoli G.CXCL12 chemokine up-regulates bone resorption and MMP-9 release by human osteoclasts: CXCL12 levels are increased in synovial and bone tissue of rheumatoid arthritis patients.J Cell Physiol2004;199:24451.
  • 14
    Pablos JL, Santiago B, Galindo M, Torres C, Brehmer MT, Blanco FJ, et al.Synoviocyte-derived CXCL12 is displayed on endothelium and induces angiogenesis in rheumatoid arthritis.J Immunol2003;170:214752.
  • 15
    De Klerck B, Geboes L, Hatse S, Kelchtermans H, Meyvis Y, Vermeire K, et al.Pro-inflammatory properties of stromal cell-derived factor-1 (CXCL12) in collagen-induced arthritis.Arthritis Res Ther2005;7:R120820.
  • 16
    Tamamura H, Fujisawa M, Hiramatsu K, Mizumoto M, Nakashima H, Yamamoto N, et al.Identification of a CXCR4 antagonist, a T140 analog, as an anti-rheumatoid arthritis agent.FEBS Lett2004;569:99104.
  • 17
    Kim KW, Cho ML, Kim HR, Ju JH, Park MK, Oh HJ, et al.Up-regulation of stromal cell–derived factor 1 (CXCL12) production in rheumatoid synovial fibroblasts through interactions with T lymphocytes: role of interleukin-17 and CD40L–CD40 interaction.Arthritis Rheum2007;56:107686.
  • 18
    Santiago B, Calonge E, Del Rey MJ, Gutierrez-Canas I, Izquierdo E, Usategui A, et al.CXCL12 gene expression is upregulated by hypoxia and growth arrest but not by inflammatory cytokines in rheumatoid synovial fibroblasts.Cytokine2011;53:18490.
  • 19
    Brentano F, Schorr O, Gay RE, Gay S, Kyburz D.RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3.Arthritis Rheum2005;52:265665.
  • 20
    Wu Y, Liu J, Feng X, Yang P, Xu X, Hsu HC, et al.Synovial fibroblasts promote osteoclast formation by RANKL in a novel model of spontaneous erosive arthritis.Arthritis Rheum2005;52:325768.
  • 21
    Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al.OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis.Nature1999;397:31523.
  • 22
    Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al.Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.Proc Natl Acad Sci U S A1998;95:3597602.
  • 23
    Fujikawa Y, Sabokbar A, Neale SD, Itonaga I, Torisu T, Athanasou NA.The effect of macrophage-colony stimulating factor and other humoral factors (interleukin-1, -3, -6, and -11, tumor necrosis factor-α, and granulocyte macrophage-colony stimulating factor) on human osteoclast formation from circulating cells.Bone2001;28:2617.
  • 24
    Scott DL, Pugner K, Kaarela K, Doyle DV, Woolf A, Holmes J, et al.The links between joint damage and disability in rheumatoid arthritis.Rheumatology (Oxford)2000;39:12232.
  • 25
    Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL.The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis.Arthritis Rheum2001;44:200917.
  • 26
    Maruotti N, d'Onofrio F, Corrado A, Cantatore FP.Why TNF-α inhibition is not sufficient to avoid juxta-articular erosions in chronic arthritis?Intern Emerg Med2012;7:1520.
  • 27
    Hoff M, Kvien TK, Kalvesten J, Elden A, Haugeberg G.Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study.Ann Rheum Dis2009;68:11716.
  • 28
    Nakamura I, Takahashi N, Jimi E, Udagawa N, Suda T.Regulation of osteoclast function.Mod Rheumatol2012;22:16777.
  • 29
    Gronthos S, Zannettino AC.The role of the chemokine CXCL12 in osteoclastogenesis.Trends Endocrinol Metab2007;18:10813.
  • 30
    Tunyogi-Csapo M, Kis-Toth K, Radacs M, Farkas B, Jacobs JJ, Finnegan A, et al.Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: fibroblast-mediated pathologic bone resorption.Arthritis Rheum2008;58:2397408.
  • 31
    Shiozawa S, Tsumiyama K, Yoshida K, Hashiramoto A.Pathogenesis of joint destruction in rheumatoid arthritis.Arch Immunol Ther Exper (Warz)2011;59:8995.
  • 32
    Karmakar S, Kay J, Gravallese EM.Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention.Rheum Dis Clin North Am2010;36:385404.
  • 33
    Maruotti N, Grano M, Colucci S, d'Onofrio F, Cantatore FP.Osteoclastogenesis and arthritis.Clin Exp Med2011;11:13745.
  • 34
    Wei L, Sun X, Kanbe K, Wang Z, Sun C, Terek R, et al.Chondrocyte death induced by pathological concentration of chemokine stromal cell-derived factor-1.J Rheumatol2006;33:181826.
  • 35
    Iwamoto T, Okamoto H, Toyama Y, Momohara S.Molecular aspects of rheumatoid arthritis: chemokines in the joints of patients.FEBS J2008;275:444855.
  • 36
    Grassi F, Piacentini A, Cristino S, Toneguzzi S, Cavallo C, Facchini A, et al.Human osteoclasts express different CXC chemokines depending on cell culture substrate: molecular and immunocytochemical evidence of high levels of CXCL10 and CXCL12.Histochem Cell Biol2003;120:391400.
  • 37
    Wright LM, Maloney W, Yu X, Kindle L, Collin-Osdoby P, Osdoby P.Stromal cell-derived factor-1 binding to its chemokine receptor CXCR4 on precursor cells promotes the chemotactic recruitment, development and survival of human osteoclasts.Bone2005;36:84053.
  • 38
    Yu X, Huang Y, Collin-Osdoby P, Osdoby P.Stromal cell-derived factor-1 (SDF-1) recruits osteoclast precursors by inducing chemotaxis, matrix metalloproteinase-9 (MMP-9) activity, and collagen transmigration.J Bone Miner Res2003;18:140418.
  • 39
    Joven B, Gonzalez N, Aguilar F, Santiago B, Galindo M, Alcami J, et al.Association between stromal cell–derived factor 1 chemokine gene variant and radiographic progression of rheumatoid arthritis.Arthritis Rheum2005;52:3546.
  • 40
    Tang CH, Chuang JY, Fong YC, Maa MC, Way TD, Hung CH.Bone-derived SDF-1 stimulates IL-6 release via CXCR4, ERK and NF-κB pathways and promotes osteoclastogenesis in human oral cancer cells.Carcinogenesis2008;29:148392.
  • 41
    Chen HT, Tsou HK, Hsu CJ, Tsai CH, Kao CH, Fong YC, et al.Stromal cell-derived factor-1/CXCR4 promotes IL-6 production in human synovial fibroblasts.J Cell Biochem2011;112:121927.
  • 42
    Chiu YC, Yang RS, Hsieh KH, Fong YC, Way TD, Lee TS, et al.Stromal cell-derived factor-1 induces matrix metalloprotease-13 expression in human chondrocytes.Mol Pharmacol2007;72:695703.
  • 43
    Kanbe K, Takemura T, Takeuchi K, Chen Q, Takagishi K, Inoue K.Synovectomy reduces stromal-cell-derived factor-1 (SDF-1) which is involved in the destruction of cartilage in osteoarthritis and rheumatoid arthritis.J Bone Joint Surg Br2004;86:296300.
  • 44
    Karouzakis E, Rengel Y, Jungel A, Kolling C, Gay RE, Michel BA, et al.DNA methylation regulates the expression of CXCL12 in rheumatoid arthritis synovial fibroblasts.Genes Immun2011;12:64352.
  • 45
    Nanki T, Nagasaka K, Hayashida K, Saita Y, Miyasaka N.Chemokines regulate IL-6 and IL-8 production by fibroblast-like synoviocytes from patients with rheumatoid arthritis.J Immunol2001;167:53815.
  • 46
    Garcia-Vicuna R, Gomez-Gaviro MV, Dominguez-Luis MJ, Pec MK, Gonzalez-Alvaro I, Alvaro-Gracia JM, et al.CC and CXC chemokine receptors mediate migration, roliferation, and matrix metalloproteinase production by fibroblast-like synoviocytes from rheumatoid arthritis patients.Arthritis Rheum2004;50:386677.
  • 47
    Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL.TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand.J Clin Invest2000;106:14818.
  • 48
    Zhang Q, Guo R, Schwarz EM, Boyce BF, Xing L.TNF inhibits production of stromal cell-derived factor 1 by bone stromal cells and increases osteoclast precursor mobilization from bone marrow to peripheral blood.Arthritis Res Ther2008;10:R37.
  • 49
    Zannettino AC, Farrugia AN, Kortesidis A, Manavis J, To LB, Martin SK, et al.Elevated serum levels of stromal-derived factor-1α are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients.Cancer Res2005;65:17009.